☆ 4.7 Article

In Vitro Killing Activities of Anidulafungin and Micafungin with and without Nikkomycin Z against Four Candida auris Clades

PHARMACEUTICS (2023)

Related references

Note: Only part of the references are listed.

Article Microbiology

Impact of FKS1 Genotype on Echinocandin In Vitro Susceptibility in Candida auris and In Vivo Response in a Murine Model of Infection

Dipti Sharma et al.

Summary: Echinocandins are frontline antifungal agents for the management of invasive infections due to multidrug resistant Candida auris. This study evaluated echinocandin resistance in 199 C. auris isolates from 30 centers across India, identifying FKS1 mutations as key factors. The study found that FKS1 genotype is a more accurate predictor of in vivo response than MIC, and other factors such as chitin content can also influence the response to echinocandins.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Add to Collection

Article Infectious Diseases

Candida auris Candidemia in Critically Ill, Colonized Patients: Cumulative Incidence and Risk Factors

Federica Briano et al.

Summary: Candida auris (C. auris) is an emerging nosocomial pathogen that has shown a sharp rise in colonization and infection cases during the COVID-19 pandemic. This study found a high cumulative incidence of C. auris candidemia in colonized patients, with multisite colonization being an independent risk factor for candidemia development.

INFECTIOUS DISEASES AND THERAPY (2022)

Add to Collection

Article Microbiology

Initial Results of the International Efforts in Screening New Agents against Candida auris

Vanice Rodrigues Poester et al.

Summary: This study evaluated the in vitro activity of diphenyl diselenide and nikkomycin Z, alone and in combination with other antifungal drugs, against Candida auris. The results showed that diphenyl diselenide had no inhibitory effect on Candida auris, while nikkomycin Z showed synergistic effects when used in combination with other antifungal drugs.

JOURNAL OF FUNGI (2022)

Add to Collection

Article

Fluconazole resistant Candida auris clinical isolates have increased levels of cell wall chitin and increased susceptibility to a glucosamine-6-phosphate synthase inhibitor

Garima Shahi et al.

Cell Surface (2022)

Add to Collection

Review Microbiology

Antifungal Combinations against Candida Species: From Bench to Bedside

Simona Fioriti et al.

Summary: Candida spp. is a major pathogen causing fungal infections in hospitalized patients and nosocomial bloodstream infections. Combination therapy has gained significant interest in the treatment of Candida infections. Various combinations of antifungal agents have shown synergistic effects against difficult-to-treat Candida species and improved outcomes compared to monotherapy. However, further in vitro and clinical studies are needed to establish the effectiveness of combination therapy as a reliable treatment option.

JOURNAL OF FUNGI (2022)

Add to Collection

Letter Infectious Diseases

Outbreak of Candida auris infection in a COVID-19 hospital in Mexico

Hiram Villanueva-Lozano et al.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Add to Collection

Article Infectious Diseases

Antifungal activity of nikkomycin Z against Candida auris

Meghan L. Bentz et al.

Summary: The in vitro activity of nikkomycin Z against C. auris showed mixed results, demonstrating activity against some, but not all isolates of the fungus.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

Add to Collection

Article Microbiology

Raman Imaging of Pathogenic Candida auris: Visualization of Structural Characteristics and Machine-Learning Identification

Giuseppe Pezzotti et al.

Summary: Invasive fungal infections caused by different species of Candida are associated with high mortality rates in various patient populations, with drug resistance being a major concern. Current identification methods for Candida species face a trade-off between speed and accuracy. The combination of machine learning and Raman spectroscopy offers a rapid, accurate, and labor-saving approach for the identification and drug efficacy assessment of Candida auris.

FRONTIERS IN MICROBIOLOGY (2021)

Add to Collection

Article Microbiology

Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum

Renato Kovacs et al.

Summary: Candida auris is an emerging and frequently multidrug-resistant pathogen for which echinocandins are the preferred treatment option. The study compared the killing activities of four echinocandins against different clades of C. auris, with rezafungin showing the same or better activity at clinically attainable trough concentration against all four clades.

MICROORGANISMS (2021)

Add to Collection

Article Microbiology

Candida auris Invasive Infections during a COVID-19 Case Surge

Blake M. Hanson et al.

Summary: Clinical cases of C. auris during a COVID-19 surge led to an investigation which found a close genetic relationship but inconclusive epidemiologic link between cases. Prolonged hospitalization due to critical illness from COVID-19 and antimicrobial use may have contributed to clinical infections.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Pharmacology & Pharmacy

In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin against Candida auris

Unai Caballero et al.

Summary: The study found that combinations of amphotericin B with anidulafungin or caspofungin provide better killing of Candida auris infections compared to monotherapy, with a lower dose requirement for amphotericin B.

PHARMACEUTICS (2021)

Add to Collection

Article Immunology

Hope on the Horizon: Novel Fungal Treatments in Development

Adriana M. Rauseo et al.

OPEN FORUM INFECTIOUS DISEASES (2020)

Add to Collection

Article Critical Care Medicine

Candida auris candidaemia in an intensive care unit - Prospective observational study to evaluate epidemiology, risk factors, and outcome

Prakash S. Shastri et al.

JOURNAL OF CRITICAL CARE (2020)

Add to Collection

Article Infectious Diseases

Antifungal Drug Repurposing

Jong H. Kim et al.

ANTIBIOTICS-BASEL (2020)

Add to Collection

Review Microbiology

Nikkomycin Z-Ready to Meet the Promise?

David J. Larwood

JOURNAL OF FUNGI (2020)

Add to Collection

Article Immunology

Multidrug-Resistant Candida auris Infections in Critically III Coronavirus Disease Patients, India, April-July 2020

Anuradha Chowdhary et al.

EMERGING INFECTIOUS DISEASES (2020)

Add to Collection

Article Immunology

Comparison of in vivo pathogenicity of four Candida auris clades in a neutropenic bloodstream infection murine model

Lajos Forgacs et al.

EMERGING MICROBES & INFECTIONS (2020)

Add to Collection

Article Infectious Diseases

Antifungal activity and killing kinetics of anidulafungin, caspofungin and amphotericin B against Candida auris

Catiana Dudiuk et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)

Add to Collection

Article Infectious Diseases

Differential recognition of Candida tropicalis, Candida guilliermondii, Candida krusei, and Candida auris by human innate immune cells

Maria J. Navarro-Arias et al.

INFECTION AND DRUG RESISTANCE (2019)

Add to Collection

Article Immunology

Hospital-Associated Multicenter Outbreak of Emerging Fungus Candida auris, Colombia, 2016

Paige A. Armstrong et al.

EMERGING INFECTIOUS DISEASES (2019)

Add to Collection

Article Infectious Diseases

Persistent candidemia despite appropriate fungal therapy: First case of Candida auris from the United Arab Emirates

Adnan Alatoom et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2018)

Add to Collection

Article Dermatology

An outbreak due to Candida auris with prolonged colonisation and candidaemia in a tertiary care European hospital

Alba Ruiz-Gaitan et al.

MYCOSES (2018)

Add to Collection

Article Immunology

Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses

Shawn R. Lockhart et al.

CLINICAL INFECTIOUS DISEASES (2017)

Add to Collection

Article Microbiology

Comparative Pathogenicity of United Kingdom Isolates of the Emerging Pathogen Candida auris and Other Key Pathogenic Candida Species

Andrew M. Borman et al.

MSPHERE (2016)

Add to Collection

Article Microbiology

Interlaboratory Variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST Methods: Should the Clinical Laboratory Be Testing This Agent?

A. Espinel-Ingroff et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)

Add to Collection

Article Oncology

Effect of nikkomycin Z and 50% human serum on the killing activity of high-concentration caspofungin against Candida species using time-kill methodology

Judit Szilagyi et al.

JOURNAL OF CHEMOTHERAPY (2012)

Add to Collection

Article Microbiology

Pharmacokinetics of Nikkomycin Z after Single Rising Oral Doses

David E. Nix et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)

Add to Collection

Article Immunology

A Multicenter, Double-Blind Trial of a High-Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis

Robert F. Betts et al.

CLINICAL INFECTIOUS DISEASES (2009)

Add to Collection

Letter Infectious Diseases

Antifungal activity against Candida albicans of nikkomycin Z in combination with caspofungin, voriconazole or amphotericin B

H. Sandovsky-Losica et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)

Add to Collection

Article Immunology

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis

Peter G. Pappas et al.

CLINICAL INFECTIOUS DISEASES (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.